Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer
Open Access
- 1 October 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 5 (10) , 2572-2579
- https://doi.org/10.1158/1535-7163.mct-06-0129
Abstract
Purpose: Trastuzumab is the cornerstone for treatment of women with HER2-overexpressing breast cancer, both in the adjuvant and in the metastatic settings. The accurate assessment of HER2 is, therefore, critical to identifying patients who may benefit from trastuzumab-based therapy. This project aimed to determine the optimal scoring method for fluorescence in situ hybridization (FISH) assay. Methods: FISH assay was done on 893 samples of breast cancer. Three scoring methods were evaluated: Her2/CEP17≥2, Her2>4, or Her2>6. Protein and gene expression were evaluated by immunohistochemistry (n = 584) and mRNA/assay/nucleic acid sequence–based amplification (NASBA; n = 90). Results: Samples were divided into five groups based on FISH results: disomic amplified and nonamplified, polysomic amplified, nonamplified, and discordant (10.8% of cases, mostly positive with Her2>4 scoring, but negative with the others). Her2/CEP17≥2 and Her2>6 scoring methods showed the best association (a) with regard to FISH scoring (κ = 0.906, P < 10−6) and (b) between FISH and immunohistochemistry (3+ as positive; κ > 0.650, P < 10−6) or NASBA (κ > 0.536, P < 10−6). Polysomy had an effect on Her2 copy number (P < 10−6), but had no effect on protein and mRNA content. Therefore, within the discordant subgroup, for which additive Her-2 gene copies are due to high polysomy, protein and mRNA levels were similar to those of the nonamplified samples. For this subgroup, the best concordance between FISH/immunohistochemistry/NASBA was observed with the Her2/CEP17 ratio and Her-2>6 scoring (68% and 58% perfect matches, respectively). No perfect matches were observed using the Her2>4 scoring method. Conclusion: Correction for chromosome-17 is the method of choice for clinical practice; Her-2>6, but not Her-2>4, could be used as an alternative. [Mol Cancer Ther 2006;5(10):2572–9]Keywords
All Related Versions
This publication has 39 references indexed in Scilit:
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast CarcinomaClinical Cancer Research, 2004
- HER-2 Testing in Breast Cancer Using Immunohistochemical Analysis and Fluorescence In Situ Hybridization : A Single-Institution Experience of 2,279 Cases and Comparison of Dual-Color and Single-Color ScoringAmerican Journal of Clinical Pathology, 2004
- Determination of HER-2 Status and Chromosome 17 Polysomy in Breast Carcinomas Comparing HercepTest and PathVysion FISH AssayAmerican Journal of Clinical Pathology, 2004
- Breast cancer classification and prognosis based on gene expression profiles from a population-based studyProceedings of the National Academy of Sciences, 2003
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences, 2003
- HER2 Testing in Patients With Breast Cancer: Poor Correlation Between Weak Positivity by Immunohistochemistry and Gene Amplification by Fluorescence In Situ HybridizationMayo Clinic Proceedings, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- Determination of Her-2/Neu Status in Breast Carcinoma: Comparative Analysis of Immunohistochemistry and Fluorescent In Situ HybridizationLaboratory Investigation, 2000